4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
10 mai 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration (wet AMD) at the 2023 ARVO Annual MeetingOn track for completion of...
4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
09 mai 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic...
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
08 mai 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic...
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
04 mai 2023 21h04 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic...
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
04 mai 2023 16h08 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic...
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
27 avr. 2023 07h00 HE
|
4D Molecular Therapeutics, Inc.
Intravitreal 4D-150 was well-tolerated with no inflammation in 14 of 15 patients and only trace mixed cells at a single timepoint in one patient; no dose-limiting toxicities, treatment-related serious...
4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy
24 avr. 2023 08h00 HE
|
4D Molecular Therapeutics, Inc.
4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of PennsylvaniaAnnounces sCFH as payload for...
4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
13 avr. 2023 08h00 HE
|
4D Molecular Therapeutics, Inc.
Interim data to be presented in an oral presentation by Dr. Arshad M. Khanani, M.D., M.A., FASRS at the 2023 ARVO Annual Meeting on Thursday, April 27, 2023 at 11:30 a.m. ETPromoted Robert Kim, M.D....
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
15 mars 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for cystic fibrosis lung disease, and 4D-310 for...
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
22 févr. 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kgCardiac biopsy demonstrated selective and...